Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IL3
REST API REST API
Homo sapiens
IL3 is differentially expressed in 122 experiments: 56 organism parts: lung, skeletal muscle, ... (54 more);, 101 disease states: normal, acute quadriplegic myopathy, ... (99 more);, 29 cell types 91 cell lines 22 compound treatments and 53 other conditions.
Synonyms IL-3, MULTI-CSF, MCGF, MGC79398, MGC79399
Orthologs IL3_BOVIN (Bos taurus)   IL3_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term extracellular space, positive regulation of cell proliferation, growth factor activity, extracellular region, cell-cell signaling, cytokine activity, positive regulation of DNA replication, immune response, nervous system development, positive regulation of peptidyl-tyrosine phosphorylation, positive regulation of survival gene product expression, interleukin-3 receptor binding, positive regulation of tyrosine phosphorylation of Stat5 protein
InterPro Term Interleukin_3
UniProt Accession P08700
Search EB-eye ENSG00000164399
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-GEOD-1563, ... (15 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-19639, E-GEOD-2450, E-GEOD-19480, E-MTAB-62, ... (17 experiments)

Factor Value U/D Experiments
SW1990
1
E-MTAB-37
primary cell
1
E-MEXP-2034
HCC1395
1
E-MTAB-37
skmc myoblast
1
E-MTAB-62
HeLa Tet-On
1
E-MTAB-62
600MPE
1
E-MTAB-62
85 more value(s).


Cell type

studied in E-GEOD-10797, E-AFMX-5, E-GEOD-18811, E-GEOD-19069, E-MTAB-24, ... (18 experiments)

Factor Value U/D Experiments
leydig cell
1
E-MTAB-25
white blood cell
1
E-GEOD-2006
stromal cell
1
E-GEOD-10797
PBMCs
1
E-GEOD-20677
epithelioid malignant mesothelioma (MM)
1
E-GEOD-21750
n/a
1
E-MTAB-24
23 more value(s).


Disease state

studied in E-GEOD-5390, E-GEOD-3307, E-GEOD-19743, E-MEXP-2069, E-GEOD-23878, ... (20 experiments)

Factor Value U/D Experiments
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
presymptomatic DMD
1
E-MTAB-62
Down syndrome
1
E-GEOD-5390
malaria (treated malaria)
1
E-MTAB-62
tumor
1
E-GEOD-19188
95 more value(s).


Compound treatment

studied in E-GEOD-1615, E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-GEOD-3720, ... (9 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-412, E-GEOD-7307, E-GEOD-5824, E-GEOD-1615
valproic acid
1
E-GEOD-1615
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
unknown
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
Cxcl12
1
E-GEOD-7307
16 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-TABM-321

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1446, E-GEOD-22278

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1432, E-GEOD-1926, E-GEOD-19519, ... (18 experiments)

Infection
studied in E-MEXP-1274

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-1309, E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-GEOD-12438, E-GEOD-3697

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-19069

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-3494

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.444 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM